Show simple item record

Verhältnis von Nutzen und Risiko der kathetergestützten Aortenklappenimplantation (TAVI) in verschiedenen Subgruppen einer unizentrischen Kohorte mit chirurgischen Hochrisikopatienten

dc.contributor.advisorPuls, Miriam PD Dr.
dc.contributor.authorViel, Tanja
dc.date.accessioned2017-08-08T09:36:51Z
dc.date.available2017-08-15T22:50:07Z
dc.date.issued2017-08-08
dc.identifier.urihttp://hdl.handle.net/11858/00-1735-0000-0023-3EC8-D
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-6428
dc.language.isodeude
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc610de
dc.titleVerhältnis von Nutzen und Risiko der kathetergestützten Aortenklappenimplantation (TAVI) in verschiedenen Subgruppen einer unizentrischen Kohorte mit chirurgischen Hochrisikopatientende
dc.typedoctoralThesisde
dc.title.translatedThe risk-to-benefit ratio of transcatheter aortic valve implantation in specific patient cohorts in a single-centre with high-risk patientsde
dc.contributor.refereeSchillinger, Wolfgang Prof. Dr.
dc.date.examination2017-08-08
dc.description.abstractengBackground: Transcatheter aortic valve implantation (TAVI) has recently developed into an acceptable alternative to conventional surgery in high-risk patients. However, information on the identification of patients gaining most benefit from this procedure is still limited. The aim of this study was to evaluate safety and efficacy of TAVI in different patient cohorts. Methods: Between August 2008 and December 2010, 180 high-risk patients underwent TAVI at our institution (97 transapical and 83 transfemoral approaches). Periprocedural complications as well as mortality and incidence of MACCE during follow-up were recorded. Results: Mean age was 82 ± 5 years, and mean logistic EuroScore 27 ± 14%. In the total cohort, 30-day mortality was 8.9% and 12-month survival (according to Kaplan-Meier-analysis) 72%, with no significant differences between the two approaches. However, a significant difference in survival was obvious after stratification of patients according to logistic EuroScore mortality estimates. Survival proportions at 1 year were 62% in patients with logistic EuroScore >40%, 71% in patients with EuroScore 20-40% and 80% in octogenarians with EuroScore <20% (P = 0.009). Furthermore, the observed median event-free survival as an indicator for morbidity ranged between 315 days in the first, 442 days in the second and 710 days in the third group (P = 0.1). Conclusions: TAVI proved to be feasible with reproducible results. However, mortality and rehospitalization rates were considerably high in specific patient cohorts, suggesting that the risk-to-benefit ratio of TAVI should be validated individually. In the present study, octogenarians with logistic EuroScore <20% could be identified as candidates apparently gaining high benefit from the procedure.de
dc.contributor.coRefereeTirilomis, Theodor Prof. Dr.
dc.contributor.thirdRefereeSigler, Matthias Prof. Dr.
dc.subject.gerTAVIde
dc.subject.gerHochrisikopatientende
dc.subject.gerMACCEde
dc.subject.engTAVIde
dc.subject.enghigh-risk patientsde
dc.subject.engMACCEde
dc.identifier.urnurn:nbn:de:gbv:7-11858/00-1735-0000-0023-3EC8-D-3
dc.affiliation.instituteMedizinische Fakultätde
dc.subject.gokfullInnere Medizin - Allgemein- und Gesamtdarstellungen (PPN619875747)de
dc.description.embargoed2017-08-15
dc.identifier.ppn89520701X


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record